^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR133B (MicroRNA 133b)

    i
    Other names: MIR133B, MicroRNA 133b, Hsa-Mir-133b, Hsa-MiR-133b, MIRN133B, Hsa-Mir-133-P3-V2, Hsa-Mir-133-P3-V1, MIMAT0000770, MiRNA133B, MI0000822, Mir-133b, RF00446
    Associations

    News

    Trials
    22d
    Oncogenic functions of polypyrimidine tract-binding protein 1 in breast cancer metabolism and progression. (PubMed, Biochem Biophys Rep)
    These findings collectively demonstrate that PTBP1 is overexpressed in BC and drives cancer-specific metabolic reprogramming associated with the Warburg effect. Therefore, PTBP1 may act as an oncogenic regulator of breast cancer metabolism and serve as a potential therapeutic target.
    Journal
    |
    PTBP1 (Polypyrimidine Tract Binding Protein 1) • MIR133B (MicroRNA 133b) • PKM (Pyruvate Kinase M1/2)
    25d
    Gramine Suppresses Cervical Cancer by Targeting CDK2: Integrated Omics-Pharmacology and In Vitro Evidence. (PubMed, Curr Issues Mol Biol)
    Collectively, our findings demonstrate that GR inhibits CC through a ncRNA-mediated suppression of CDK2, leading to reduced HeLa cell proliferation and migration and enhanced apoptosis. These results provide a mechanistic rationale for developing GR as a candidate agent for targeted therapy and immuno-combination strategies in CC.
    Preclinical • Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • LINC00958 (Long Intergenic Non-Protein Coding RNA 958) • MIR133B (MicroRNA 133b)
    2ms
    Retraction: MicroRNA-133b Inhibits Proliferation, Cellular Migration, and Invasion via Targeting LASP1 in Hepatocarcinoma Cells. (PubMed, Oncol Res)
    [This retracts the article DOI: 10.3727/096504017X14850151453092.].
    Journal
    |
    LASP1 (LIM And SH3 Protein 1) • MIR133B (MicroRNA 133b)
    2ms
    Hsa_circ_PCNT sponges hsa-miR-133b to promote SHH medulloblastoma via TAGLN2. (PubMed, Cell Mol Life Sci)
    The results show that hsa_circ_PCNT promotes SHH-MB aggression through the hsa-miR-133b /TAGLN2 pathway. In summary, our research demonstrates that hsa_circ_PCNT occupies a crucial position in SHH-MB and emerges as a potential therapeutic target.
    Journal
    |
    MIR133B (MicroRNA 133b)
    2ms
    MicroRNA Signatures and Machine Learning Models for Predicting Cardiotoxicity in HER2-Positive Breast Cancer Patients. (PubMed, Pharmaceuticals (Basel))
    Background: HER2-positive breast cancer patients receiving chemotherapy and targeted therapy (including anthracyclines and trastuzumab) face an elevated risk of cardiotoxicity, which can lead to long-term cardiovascular complications... Circulating miRNAs show promise as biomarkers for predicting cardiotoxicity in breast cancer patients. Machine learning approaches may enhance miRNA-based risk stratification, enabling personalized monitoring and early cardioprotective interventions.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MIR155 (MicroRNA 155) • MIR199A1 (MicroRNA 199a-1) • MIR143 (MicroRNA 143) • MIR17 (MicroRNA 17) • MIR199A (MicroRNA 199a) • miR-185 (MicroRNA 185) • MIR124-2 (MicroRNA 124-2) • MIR133B (MicroRNA 133b) • MIR145 (MicroRNA 145) • MIR124-3 (MicroRNA 124-3)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    3ms
    Isoform-Specific Transcriptomic Effects of miR-133A1, miR-133A2, and miR-133B in a Colorectal Cancer Cell Line. (PubMed, Genes (Basel))
    These findings suggest that miR-133 isoforms exert both shared and subtly divergent regulatory functions in colorectal cancer, coordinating apoptosis, proliferation, migration, and signaling network modulation. Isoform-specific transcriptional regulation of miR-133 may contribute to tumor progression and represents a potential biomarker and therapeutic target in CRC.
    Preclinical • Journal
    |
    MIR133A1 (MicroRNA 133a-1) • MIR133B (MicroRNA 133b)
    4ms
    Retraction: MicroRNA-133b Inhibits Cell Proliferation and Invasion in Osteosarcoma by Targeting Sirt1. (PubMed, Oncol Res)
    [This retracts the article DOI: 10.3727/096504016X14826089198805.].
    Journal
    |
    SIRT1 (Sirtuin 1) • MIR133B (MicroRNA 133b)
    5ms
    Meta-Analysis of Differentially Expressed Non-Coding RNA Signatures (lncRNAs, miRNAs, and snoRNAs) in Parkinson's Disease. (PubMed, Behav Brain Res)
    Network analysis uncovered two divergent interactomes - a focused upregulated network (4 hubs/32 proteins/151 edges) versus an extensive downregulated network (5 hubs/245 proteins/2,826 edges) - suggesting the latter's predominant role in PD progression. Our findings systematically decode ncRNA regulatory architecture in PD, delivering both mechanistic insights and clinically actionable targets for early diagnosis and therapeutic development.
    Retrospective data • Journal
    |
    NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • MIR182 (MicroRNA 182) • MIR18A (MicroRNA 18a) • MIR451A (MicroRNA 451a) • ATXN8OS (ATXN8 Opposite Strand LncRNA) • MIR133B (MicroRNA 133b)
    5ms
    LncRNA LINC02381/miR-133b axis promotes tumorigenesis and predicts survival in pancreatic cancer. (PubMed, Discov Oncol)
    Elevated levels of LINC02381 are associated with diminished survival outcomes in pancreatic cancer patients, suggesting its potential as a prognostic biomarker for this malignancy. These findings warrant further investigation to elucidate the role of LINC02381 in pancreatic cancer progression and patient prognosis.
    Journal
    |
    LINC02381 (Long Intergenic Non-Protein Coding RNA 2381) • MIR133B (MicroRNA 133b)
    6ms
    Layered double hydroxide-loaded si-NEAT1 regulates paclitaxel resistance and tumor-associated macrophage polarization in breast cancer by targeting miR-133b/PD-L1 (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    LDH@si-NEAT1 reduces paclitaxel resistance of breast cancer cells and inhibits TAM polarization by targeting the miR-133b/PD-L1 axis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD163 (CD163 Molecule) • IL10 (Interleukin 10) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • IL4 (Interleukin 4) • MIR133B (MicroRNA 133b)
    |
    PD-L1 expression
    |
    paclitaxel
    7ms
    Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment. (PubMed, Biology (Basel))
    The knowledge of this molecular pathogenesis has not yet been translated into clinical practice, apart from the use of cetuximab, an EGFR antibody...Liquid biopsies, either resorting to circulating tumor cells, extracellular vesicles or cell-free nucleic acids, have the potential to bypass this problem, and have potential prognostic and staging value. We critically review the current knowledge on the molecular, genetic and epigenetic alterations in oral cancer, as well as the applications and challenges of liquid biopsies in its diagnosis, follow-up, and prognostic stratification.
    Review • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1) • ADAM9 (ADAM Metallopeptidase Domain 9) • MIR21 (MicroRNA 21) • MGAM (Maltase-Glucoamylase) • SOX17 (SRY-Box Transcription Factor 17) • MIR100 (MicroRNA 100) • MIR211 (MicroRNA 211) • MIR221 (MicroRNA 221) • MIR184 (MicroRNA 184) • MIR31 (MicroRNA 31) • MIR375 (MicroRNA 375) • CTTN (Cortactin) • MIR133B (MicroRNA 133b) • MIR138 (MicroRNA 138) • MIR200 (MicroRNA 200) • MIR203A (MicroRNA 203a) • MIR222 (MicroRNA 222)
    |
    Erbitux (cetuximab)